Key result
CREBH deletion in Ldlr(-/-) mice significantly increased atherosclerotic lesions in the aortas and worsened the atherogenic lipid profile compared to Ldlr(-/-) mice.
Why the study?
Does CREBH deficiency accelerate diet-induced atherosclerosis and alter lipoprotein metabolism in Ldlr-/- mice?
Does CREBH deficiency accelerate diet-induced atherosclerosis and alter lipoprotein metabolism in Ldlr-/- mice?
CREBH is a critical regulator of lipoprotein metabolism, and its deletion accelerates diet-induced atherosclerosis, suggesting that enhancing hepatic CREBH activity could be a novel therapeutic strategy.
CREBH deficiency modulates lipoproteins in Ldlr(-/-) mice; leaves open any role in human atherosclerosis.
OBJECTIVE: Liver-enriched transcription factor cAMP-responsive element-binding protein H (CREBH) regulates plasma triglyceride clearance by inducing lipoprotein lipase cofactors, such as apolipoprotein A-IV (apoA-IV), apoA-V, and apoC-II. CREBH also regulates apoA-I transcription. This study aims to determine whether CREBH has a role in lipoprotein metabolism and development of atherosclerosis. APPROACH AND RESULTS: CREBH-deficient Creb3l3(-/-) mice were bred with Ldlr(-/-) mice creating Ldlr(-/-) Creb3l3(-/-) double knockout mice. Mice were fed on a high-fat and high-sucrose Western diet for 20 weeks. We showed that CREBH deletion in Ldlr(-/-) mice increased very low-density lipoprotein-associated triglyceride and cholesterol levels, consistent with the impairment of lipoprotein lipase-mediated triglyceride clearance in these mice. In contrast, high-density lipoprotein cholesterol levels were decreased in CREBH-deficient mice, which was associated with decreased production of apoA-I from the liver. The results indicate that CREBH directly activated Apoa1 gene transcription. Accompanied by the worsened atherogenic lipid profile, Ldlr(-/-) Creb3l3(-/-) mice developed significantly more atherosclerotic lesions in the aortas than Ldlr(-/-) mice. CONCLUSIONS: We identified CREBH as an important regulator of lipoprotein metabolism and suggest that increasing hepatic CREBH activity may be a novel strategy for prevention and treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Park et al. (2016) studied Atherosclerosis. CREBH deletion (Creb3l3(-/-)) vs. Ldlr(-/-) mice was evaluated on Atherosclerotic lesions in the aortas. CREBH deletion in Ldlr(-/-) mice significantly increased atherosclerotic lesions in the aortas and worsened the atherogenic lipid profile compared to Ldlr(-/-) mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: